Regent Pacific GroupRPGLF 7 EBIT per Share is $-0.02 as of Dec. 2025. GuruFocus rates RPGLF with a GF Score™ of 7/100. The stock has 7 warning signs investors should review. Among 808 Drug Manufacturers companies, Regent Pacific Group ranks better than 92.08% on this metric.
Regent Pacific Group's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 60.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 47.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 26.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Regent Pacific Group's EBIT per Share or its related term are showing as below:
RPGLF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -60.9 Med: 10.5 Max: 60
Current: 60
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Regent Pacific Group was 60.00% per year. The lowest was -60.90% per year. And the median was 10.50% per year.
RPGLF's 3-Year EBIT Growth Rate is ranked better than 92.08% of 808
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs RPGLF: 60.00
Regent Pacific Group (OTCPK:RPGLF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Regent Pacific Group EBIT per Share Related Terms
Regent Pacific Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Regent Pacific Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regent Pacific Group (RPGLF) has a EBIT per Share of $-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Regent Pacific Group and its competitors. According to the industry distribution chart, Regent Pacific Group ranks #64 out of 808 companies in the Drug Manufacturers industry, placing it in the top 7.9%.
Is Regent Pacific Group's EBIT per Share too high?
Regent Pacific Group's current EBIT per Share is $-0.02. Based on the distribution chart, Regent Pacific Group ranks #64 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Regent Pacific Group has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #64 out of 808 companies for EBIT per Share. This places Regent Pacific Group in the top 8% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Regent Pacific Group and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current EBIT per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current EBIT per Share of $-0.02. The current EBIT per Share is $-0.02. Regent Pacific Group's overall GF Score™ is 7/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current EBIT per Share is $-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
7GF Score
Get the complete analysis for RPGLF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPGLF has been successfully added to your 
